Tiziana Life Sciences plc, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology, inflammation, and infectious diseases. Its lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. The company is also developing Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients. It has a collaboration agreement with FHI Clinical to conduct a Phase 2 clinical trials for treating hospitalized severe COVID-19 patients with intranasal foralumab. The company was incorporated in 1998 and is based in London, the United Kingdom.
